These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 8222482)

  • 61. Absorption and biological effect of intraperitoneal insulin administration in patients with terminal renal failure treated by continuous ambulatory peritoneal dialysis (CAPD).
    Peetoom JJ; Willekens FL; Meinders AE
    Neth J Med; 1985; 28(10):435-41. PubMed ID: 3908952
    [No Abstract]   [Full Text] [Related]  

  • 62. Pyridinium crosslinks in patients on haemodialysis and continuous ambulatory peritoneal dialysis.
    Ibrahim S; Mojiminiyi S; Barron JL
    Nephrol Dial Transplant; 1995 Dec; 10(12):2290-4. PubMed ID: 8808228
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Pharmacokinetics of cefprozil in healthy subjects and patients with renal impairment.
    Shyu WC; Pittman KA; Wilber RB; Matzke GR; Barbhaiya RH
    J Clin Pharmacol; 1991 Apr; 31(4):362-71. PubMed ID: 2037710
    [TBL] [Abstract][Full Text] [Related]  

  • 64. [Dosage of erythropoietin in children treated with hemodialysis and continuous ambulatory peritoneal dialysis].
    Sieniawska M; Roszkowska-Blaim M
    Pediatr Pol; 1995 Dec; 70(12):1023-8. PubMed ID: 8649941
    [TBL] [Abstract][Full Text] [Related]  

  • 65. A comparative study of continuous ambulatory peritoneal dialysis and center hemodialysis. Efficacy, complications, and outcome in the treatment of end-stage renal disease.
    Charytan C; Spinowitz BS; Galler M
    Arch Intern Med; 1986 Jun; 146(6):1138-43. PubMed ID: 3718101
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Serum CA-125 level in end-stage renal disease patients maintained on chronic peritoneal dialysis or hemodialysis: the effect of continuous presence of peritoneal fluid, peritonitis, and peritoneal catheter implantation.
    Bastani B; Chu N
    Am J Nephrol; 1995; 15(6):468-72. PubMed ID: 8546167
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Effect of dialysis modalities on gastric myoelectrical activity in end-stage renal disease patients.
    Lee SW; Song JH; Kim GA; Yang HJ; Lee KJ; Kim MJ
    Am J Kidney Dis; 2000 Sep; 36(3):566-73. PubMed ID: 10977789
    [TBL] [Abstract][Full Text] [Related]  

  • 68. [Comparison of quality of life in continuous ambulatory peritoneal dialysis and hemodialysis patients].
    Wang T; Liu B; Ye RG
    Zhonghua Nei Ke Za Zhi; 1993 Nov; 32(11):754-6. PubMed ID: 8137656
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Atenolol pharmacokinetics in patients on continuous ambulatory peritoneal dialysis.
    Salahudeen AK; Wilkinson R; McAinsh J; Bateman DN
    Br J Clin Pharmacol; 1984 Sep; 18(3):457-60. PubMed ID: 6487486
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Moxalactam kinetics during chronic ambulatory peritoneal dialysis.
    Singlas E; Boutron HF; Merdjan H; Brocard JF; Pocheville M; Fries D
    Clin Pharmacol Ther; 1983 Sep; 34(3):403-7. PubMed ID: 6224624
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Quinidine pharmacokinetics in continuous ambulatory peritoneal dialysis.
    Chin TW; Pancorbo S; Comty C
    Clin Exp Dial Apheresis; 1981; 5(4):391-7. PubMed ID: 7341025
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Roxithromycin disposition in patients on continuous ambulatory peritoneal dialysis.
    Lam YW; Flaherty JF; Yumena L; Schoenfeld PY; Gambertoglio JG
    J Antimicrob Chemother; 1995 Jul; 36(1):157-63. PubMed ID: 8537262
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Alprazolam in end-stage renal disease: I. Pharmacokinetics.
    Schmith VD; Piraino B; Smith RB; Kroboth PD
    J Clin Pharmacol; 1991 Jun; 31(6):571-9. PubMed ID: 1880224
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Ranitidine pharmacokinetics in continuous ambulatory peritoneal dialysis.
    Sica DA; Comstock T; Harford A; Eshelman F
    Eur J Clin Pharmacol; 1987; 32(6):587-91. PubMed ID: 3653228
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Pharmacokinetics of teicoplanin in patients on continuous ambulatory peritoneal dialysis.
    Traina GL; Gentile MG; Fellin G; Rosina R; Cavenaghi L; Buniva G; Bonati M
    Eur J Clin Pharmacol; 1986; 31(4):501-4. PubMed ID: 2949981
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Exercise capacity in chronic renal failure patients managed by continuous ambulatory peritoneal dialysis.
    Beasley CR; Smith DA; Neale TJ
    Aust N Z J Med; 1986 Feb; 16(1):5-10. PubMed ID: 3458447
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Pharmacokinetics and metabolism of intravenous and oral fleroxacin in subjects with normal and impaired renal function and in patients on continuous ambulatory peritoneal dialysis.
    Stuck AE; Frey FJ; Heizmann P; Brandt R; Weidekamm E
    Antimicrob Agents Chemother; 1989 Mar; 33(3):373-81. PubMed ID: 2499248
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Pharmacokinetics of calcitriol in continuous ambulatory and cycling peritoneal dialysis patients.
    Salusky IB; Goodman WG; Horst R; Segre GV; Kim L; Norris KC; Adams JS; Holloway M; Fine RN; Coburn JW
    Am J Kidney Dis; 1990 Aug; 16(2):126-32. PubMed ID: 2382648
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Amikacin pharmacokinetics during continuous ambulatory peritoneal dialysis.
    Smeltzer BD; Schwartzman MS; Bertino JS
    Antimicrob Agents Chemother; 1988 Feb; 32(2):236-40. PubMed ID: 3364945
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Pharmacokinetics of cefotaxime in dialysis patients.
    Andrassy K
    Diagn Microbiol Infect Dis; 1995; 22(1-2):85-7. PubMed ID: 7587055
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.